Last reviewed · How we verify
VB15010
At a glance
| Generic name | VB15010 |
|---|---|
| Sponsor | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VB15010 CI brief — competitive landscape report
- VB15010 updates RSS · CI watch RSS
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd. portfolio CI